Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Placebo-Controlled Phase III Trial of Cobitolimod in Ulcerative Colitis
2021-002549-13Phase 3Terminated
- Sponsor
- InDex Pharmaceuticals
- Start
- Jun 2021
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Cobitolimod with Placebo (2 arms). Primary endpoint: Primary Endpoint: Induction. Started Jun 2021; status: terminated.
02
Drugs
cobitolimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2021-002549-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002549-13.